Losartan, enalapril and amlodipine reduced the number of premature ventricular contractions (PVCs) in patients with essential hypertension as well as blood pressure. The effect of losartan was the most prominent among the three drugs.
Premature ventricular contractions have been recognized as a marker of remodelled hypertensive heart. The prognosis of the patients with hypertension was better when they had no PVC in the ambulatory electrocardiogram (ECG). [1] [2] [3] [4] Fibrosis and hypertrophy due to hypertension, which constitute a substrate of PVCs, could regress after the administration of antihypertensive drugs. 5 Whether antihypertensive drugs could decrease PVC is not known. In this study, we investigated whether losartan, enalapril and amlodipine could reduce PVC in hypertensive patients.
Fifty-five consecutive patients with essential hypertension were enrolled in this study. Inclusion criteria were as follows: WHO class I or II essential hypertension (systolic blood pressure 150 mm Hg and/or diastolic blood pressure 90 mm Hg), age 20-85 years old and PVC 41000 per day in ambulatory ECG. Losartan 50 mg day À1 was administered in initial 30 patients. Enalapril 5 mg day À1 or amlodipine 5 mg day À1 was given to the next 25 patients (n ¼ 10 for enalapril, n ¼ 15 for amlodipine). Sixteen patients were randomly selected after 24 weeks of administration of the first drug, which was switched to another. The second drug was administered for the following 24 weeks so that crossover comparisons were possible between losartan and enalapril, and between losartan and amlodipine (losartan vs enalapril in six patients, losartan vs amlodipine in 10 patients).
Patients visited our clinical office once every month and complete physical examination including blood pressure was reviewed. A standard surface ECG, Holter ECG and laboratory examinations were taken before, at the eighth week and the twentyfourth week after the drug administration. Chest X-ray film and echocardiography were examined before and the twenty-fourth week after the drug administration. ECG parameters were measured independently by one examiner whereas the drug treatment and the patient name were masked. Cornell voltage duration ((R aVL þ S V3) Â QRS duration) and Sokolow-Lyon voltage (SV1 þ RV5/ RV6) were calculated. 6 The total number of PVCs per 24 h was calculated from the raw data for the comparison. The actual recording time was distributed from 23 h 20 min to 24 h 10 min.
Before inclusion in this study, patients gave informed consent. The study design was approved by the Ethical Committee of Kyoto Prefectural University of Medicine. Analysis of variance was used to detect statistical differences among the three treatment groups. Repeated measure analysis of variance was used to compare temporal differences within the same treatment group. Analysis of variance rank-sum test was used for skewed data for Holter data. Data were presented as mean±s.e.m. except PVC data that are mean (95% confidence interval). Po0.05 was considered as statistically significant.
Among the three groups (losartan, enalapril and amlodipine), ages were not statistically different (losartan 67 ± 2, enalapril 61 ± 5 and amlodipine 67 ± 3). Cardiothoracic ratio in chest X-ray examination was at around 50% in all groups and was not changed after antihypertensive treatment for 24 weeks.
Changes in blood pressure during the drug treatment in three groups were as follows (mm Hg): systolic blood pressure/diastolic blood pressure ¼ 155 ± 2/85 ± 3 with losartan, 162 ± 5/95 ± 3 with enalapril and 162±4/90±4 with amlodipine. They were not statistically different before treatment among three groups, but decreased significantly after the treatment in all groups (131±3/74±3 with losartan, 135±5/80±6 with enelapril and 127 ± 4/69 ± 4 with amlodipine; all Po0.001). Blood pressures were not different at the twenty-fourth week after the treatment among the three groups (P ¼ 0.99).
Echocardiography showed slightly enlarged left atrial dimension (40±1 mm) and elevated A/E (1.3 ± 0.1). Otherwise, there was no apparent abnormality. The measured data in echocardiography were not changed after the treatment. Left ventricular mass index (area-length method) was changed as follows after each treatment: 112 ± 4-106 ± 6 g m Figure 1 shows the changes in the number of PVC per 24 h. They were not significantly different before treatment. The number was decreased significantly 8 and 24 weeks after the treatment with losartan (P ¼ 0.004). In the other groups, the average was slightly decreased 8 weeks after the treatment with enelapril and 24 weeks after the treatment with amlodipine, but the difference did not reach statistical significance. PVC was recorded mainly during the daytime in four patients, at night in three patients and without any definite trend in the remaining 48 patients. Daily heart beats per 24 h were not changed in all treatment groups after 24 weeks: (mean (95% confidence interval) QT intervals were measured in the standard 12-lead ECG before and after the treatment in the three groups. The maximum (the longest) QT interval in the same ECG record was adopted for comparison among the three groups. In losartan group, QT intervals were prolonged significantly from 0.369 ± 0.005 to 0.386 ± 0.005 (P ¼ 0.035). However, this apparent prolongation was mainly due to the increase in RR intervals (0.888 ± 0.026 s before treatment; 0.939 ± 0.027 s after treatment; ns, P ¼ 0.08). QT intervals were not changed in the other two groups (0.385 ± 0.01-0.382 ± 0.008 with enalapril and 0.388 ± 0.01-0.373 ± 0.01 with amlodipine). RR intervals were changed from 0.948±0.052 to 0.960±0.030 s in enalapril group and from 0.913±0.037 to 0.855± 0.027 s in amlodipine group (ns, P ¼ 0.123).
QRS duration was 93.5 ± 3.8 ms in control, 90.4±1.7 ms in losartan, 91.0±3.3 ms in enalapril and 92.8 ± 4.1 ms in amlodipine. Sokolow-Lyon voltage was 32.9 ± 2.3 mV in control, 29.1 ± 1.3 mV in losartan, 32.6±2.5 mV in enalapril and 28.5±2.5 mV in amlodipine. Cornell voltage duration was 1712 ± 170 in control, 1552 ± 114 in losartan, 2076 ± 442 in enalapril and 1666 ± 251 in amlodipine. All values were not statistically significant among each group (Sokolow-Lyon: P ¼ 0.98; Cornell: P ¼ 0.77).
A crossover comparison of the drug effects showed that the reduction of PVC was apparent in a comparison between amlodipine (5410 (1360-15 487)) and losartan (1082 (3-5365), n ¼ 10, P ¼ 0.045). In a comparison between enalapril and losartan, PVC was 5456 (1758-30 309) in the enalapril group and 3380 (1063-5364) in the losartan group (n ¼ 6, P ¼ 0.24).
This study showed that antihypertensive treatment, especially with losartan, decreased the number of PVCs in patients with hypertension. The treatment of hypertension was 'antiarrhythmic' against ventricular arrhythmia. This effect could be attributable to the consequence of haemodynamic change after the reduction of blood pressure and/or pharmacological pleiotropic effects.
It is well known that the number of PVC is highly variable. [7] [8] [9] [10] Thus, it is a limitation of our study that there was no control group that was followed up In the losartan group, PVC was decreased significantly after the treatment (P ¼ 0.004). In the other groups, there was no statistical difference between before and after the treatment although the largest number of PVC was decreased. *Po0.05 compared with the baseline before each drug administration.
Research Letter without any antihypertensive drugs for 24 weeks. Previous reports concluded, however, that the number of PVC should be reduced by 65-90% after the treatment when the effect was truly attributable to the agent. 7, 9 In our study, losartan reduced PVC by 90% and amlodipine reduced it by 56% 24 weeks after the treatment, respectively. The results of the crossover study suggested that the effect of our agents were not time-dependent.
Although there was no apparent change in echocardiography, QT intervals were prolonged in the losartan group. This change may explain the present data, but we should be cautious of the interpretation because of the small study population.
